期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

沙利度胺在炎性肠病中的应用 被引量：1

The application of thalidomide in inflammatory bowel disease
原文传递
导出
摘要 炎性肠病是一种慢性疾病，给患者带来长期的痛苦，由于目前该病病因和发病机制尚不十分清楚，因此缺乏有效的治疗手段。近年来，国内外很多研究者应用沙利度胺治疗该类疾病取得了很好的效果。该文着重综述沙利度胺的药动学，治疗炎性肠病作用机制的研究新进展、使用剂量、方法和注意事项，以便更好地了解沙利度胺的新用途，为治疗炎性肠病提供一个新方法。
作者 徐家骅(综述) 黄瑛(审校)
机构地区 复旦大学附属儿科医院消化内科
出处 《国际儿科学杂志》 2009年第1期54-56,共3页 International Journal of Pediatrics
关键词 炎性肠疾病 沙立度胺 药动学 发病机制
分类号 R574 [医药卫生—消化系统] R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献24

  • 1Casella G, De Marco E, Monti C, et al. The therapeutic role of thalidomide in inflammatory bowel disease. Minerva Gastroenterol Dietol, 2006,52 (3) : 293-301.
  • 2Bariol C, Meagher AP, Vickers CR, et al. Early studies on the safety and efficacy of thalido-mide for symptommatic inflammatory bowel disease. J Gastroenterol Hepatol,2002,17(2) : 135-139.
  • 3Lazzerini M,Martelossi S,Marchetti F,et al.Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results. Aliment Pharmacol Ther, 2007,25 (4) : 419-427.
  • 4Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn' s disease: An open-label trial. Gastroenterology, 1999,117(6) : 1271-1277.
  • 5施佳平,刘洪江.反应停的药学研究及临床应用现状[J].江西中医学院学报,2006,18(4):72-73. 被引量：1
  • 6Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol,2001,57(5) :365-376.
  • 7Ogata H, Hibi T. Cytokine and anti-cytokine therapies for inflammatory bowel disease. Curt Pharm Des, 2003,9 (14) : 1107-1113.
  • 8Karrow NA, Guo TL, Zhang LX, et al. Thalidomide modulation of immune response in female B6C3F1 mice a host resistance study. Int Immunopharmacol,2003,3( 10-11 ) : 1447-1456.
  • 9Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and inter-leukin 12 production in patients with chronic active Crohn' s disease. Gut,2002,50(2) : 196-200.
  • 10Kim YS,Kim JS,Jung HC,et al.The effects of thalidomide on the stimulation of NF-kappaB activity and TNF-alpha production by lipopolysaceharide in a human colonic epithelial cell line. Mol Cells,2004,17(2) :210-216.

二级参考文献36

  • 1许戈良,荚卫东,马金良,余继海.槐耳清膏体外抑制血管生成的实验研究[J].中国药理学通报,2003,19(12):1410-1412. 被引量：33
  • 2井丽萍,张凤奎,薛峰.血管滤泡性淋巴结增生症伴克罗恩病一例[J].中华内科杂志,2005,44(2):142-142. 被引量：2
  • 3S. Singhal,J. Mehta,Thalidomide in cancer,Biomed Pharmacother,2002,56(1): 4-12.
  • 4Macpherson GR, Franks M, Tomoaia-Cotisel A et al. Current status of thalidomide and its role in the treatment of metastatic prostate cancer[J].Critical Reviews in Oncology/Hematology,2003,46:S49-/S57
  • 5Bisacchi D, Benelli R, Vanzetto C et al.Anti-angiogenesis and angioprevention:mechanisms,problems and perspectives[J].Cancer Detection and Prevention,2003,27(3):229-38.
  • 6Musto P. Thalidomide therapy for myelodysplastic syndromes:current status and future perspectives[J].Leukemia Research,2004,28(4):325-32.
  • 7Kenyon BM, Fiona Browne, D'amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization[J].Exp Eye Res,1997,64(6):971-8.
  • 8Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent[J].Biochemical Pharmacology,1998,55(11):1827-34.
  • 9Myounga H, Hongb SD, Kima YY et al.Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma[J].Cancer Letters,2001,163(2):191-200.
  • 10Amato RJ. Thalidomide therapy for renal cell carcinoma,Critical Reviews in Oncology/Hematology,2003,46:S59-/S65.

共引文献19

同被引文献7

引证文献1

二级引证文献3

国际儿科学杂志
2009年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部